Gastrointestinal Stromal Tumor (GIST) - Single Center Experience of prolonged treatment with Imatinib

Autor: T. Armbrust, László Füzesi, Claus Langer, Giuliano Ramadori, B. Gunawan, Christian G. Schindler
Rok vydání: 2005
Předmět:
Male
Time Factors
Single Center
Gastroenterology
Piperazines
Tyrosine-kinase inhibitor
0302 clinical medicine
Risk Factors
Neoplasm Metastasis
Stromal tumor
GiST
Liver Neoplasms
Nucleic Acid Hybridization
DNA
Neoplasm
Middle Aged
Prognosis
Immunohistochemistry
3. Good health
030220 oncology & carcinogenesis
Benzamides
Imatinib Mesylate
Female
030211 gastroenterology & hepatology
Safety
medicine.drug
Adult
medicine.medical_specialty
Gastrointestinal Stromal Tumors
medicine.drug_class
Antineoplastic Agents
03 medical and health sciences
Internal medicine
medicine
Humans
Adverse effect
Protein Kinase Inhibitors
neoplasms
Aged
Retrospective Studies
Chromosome Aberrations
business.industry
Retrospective cohort study
Imatinib
Surgery
Pyrimidines
Neoplasm Recurrence
Local
Tomography
X-Ray Computed
business
Zdroj: Zeitschrift für Gastroenterologie. 43:267-273
ISSN: 1439-7803
0044-2771
Popis: Background: The tyrosine kinase inhibitor imatinib has been introduced into the treatment of gastrointestinal stromal tumors (GIST). Here we report our results of prolonged treatment in comparison to a similar group of GIST patients who had died before imatinib became available. Methods: Fourteen patients with recurrent or metastatic GIST were treated with imatinib. Clinical data and tumor samples of ten patients from the pre-imatinib era were available for comparison. Comparative genomic hybridisation (CGH) was performed on tumors to identify changes that may predict response to treatment. Results: Fourteen patients were treated, mean treatment time 22.3 months (1 non-response, 2 progression after initial response, 2 stable diseases, 8 partial responses, 1 complete response). Adverse side effects were mild in general. Survival was higher in the treated group (41.1 months vs. 34.8 months in the historical group). Eleven treated patients are alive. CGH analysis showed comparable numbers of chromosomal aberations in both groups. Conclusion: Prolonged treatment with imatinib is safe and effective in patients with recurrent or metastatic GIST.
Databáze: OpenAIRE
Externí odkaz: